CA2170754C - Injectable compositions for soft tissue augmentation - Google Patents
Injectable compositions for soft tissue augmentation Download PDFInfo
- Publication number
- CA2170754C CA2170754C CA002170754A CA2170754A CA2170754C CA 2170754 C CA2170754 C CA 2170754C CA 002170754 A CA002170754 A CA 002170754A CA 2170754 A CA2170754 A CA 2170754A CA 2170754 C CA2170754 C CA 2170754C
- Authority
- CA
- Canada
- Prior art keywords
- elastin
- composition
- collagen
- tissue
- soft tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Injectable implant compositions for soft tissue augmentation comprise elasti n and collagen and a biocompatible carrier. An injectable implant composition for soft tissue augmentation is derived from the ligamentum nuchae which has been treated to remove non-collagenous and non-elastinous proteins. Methods of making an injectable implant composition for soft tissue augmentation from the ligamentum nuchae are described.
Description
WO 95/07095 ~ ~ j~ PCT/US94/10223 r TITLE
INJECTABLE COMPOSITIONS FOR
SOFT TISSUR Arrr_~~p,TION
BACKGROUND OF THE INVENTION
Field of the Invention The present invention relates to injectable compositions having primary utility for soft tissue augmentation.
Related Background Over the years, many attempts have been made to develop injectable compositions for soft tissue augmentation, especially breast augmentation. Although in recent years the emphasis in breast augmentation has been on surgically implantable breast prostheses, injectable compositions offer the very important advantage of being able to avoid a surgical procedure.
Some of the early attempts to make injectable compositions for breast augmentation involved the use of silicone gel. However, silicone injected subcutaneously has a tendency to migrate into the surrounding tissue causing, among other problems, SUBSTITUTE SHEET (RULE 26) WO 95/07095 PCTlUS9.~/10223 granulomas. Accordingly, injectable liquid gels are no longer in use.
Subsequently, injectable collagen in suspension became the composition of choice. However, natural collagen , has a great tendency to be resorbed. Therefore, in order to have soft tissue augmentation that did not dissipate shortly after injection, it was found necessary to cross link the collagen with agents such as glutaraldehyde. Cross linking inhibits resorption.
However, recently the use of glutaraldehyde cross linked collagen has itself come under attack.
SUN~ARY OF THE INVENTION
The present invention addresses the problems encountered in the prior art by using injectable compositions containing non-cross linked collagen together with significant amounts of elastin. Elastin has a much lower tendency than collagen toward resorption. Moreover, it is believed that elastin attracts fibroblasts which in turn produce new native connective tissue. Thus, when a composition according to the present invention is injected subcutaneously into soft tissue, as the injected collagen is being resorbed, new native connective tissue is being generated, until a steady state situation has been achieved.
Another advantage of using elastin is that, in suspension, it has a lower viscosity and hence flows much more readily than collagen. This characteristic of elastin makes it easier to inject higher solids content compositions than is possible when using collagen alone.
As indicated above, one use for the compositions of the present invention is for breast augmentation. Another SUBSTITUTE SHEET (RULE 26) WO 95/07095 ; PCT/US94/10223 cosmetic application is as a dermal implant to remove wrinkles, primarily around the face and neck. In addition, there are medical applications as well. For a example, compositions of the present invention can be used in connection with overcoming urinary incontinence. In this latter application, a composition according to the present invention would be injected into the area of the urethral sphincter.
Other possible uses for the compositions of the present invention include load-bearing tissue augmentation, for example, under a corn, and general and specific contour improvements, for example, for nose contour corrections and to correct viral pock marks and acne scars. For load bearing tissue augmentation, the composition of the present invention would be injected between the load bearing tissue, for example the corn, and the load exerting medium, for example the bone. To alleviate skin contour defects, such as viral infection pock marks and acne scars, the composition of the present invention would be injected into the soft tissue beneath the imperfection. Similarly, to change the contour of a person's nose, the composition of the present invention would be injected into the soft tissue of the nose.
While collagen has been used previously for the above-described applications, it has generally been in the form of cross-linked collagen. Even with cross-linked collagen, however, the resorption time is often unacceptably short, especially after repeated injections. Indeed, injections of cross-linked collagen must frequently be repeated several times over a short time span before adequate augmentation can be achieved. In addition, glutaraldehyde cross-linked collagen tends to cause tissue reactions in some patients and, also, there is some concern about SUBSTITUTE SHEET (RULE 26) potential immunolcgical problems associated with the use of collagen that has been cross-linked with glutaraldehyde. Cross linking agents like glutaraldehyde are known to be toxic and there is S concern that repeated injections of glutaraldehyde-containing compositions may produce: progressively more severe immune reactions and increasingly rapid resorption. The compositions of tree present invention, on the other hand, are believed to have much longer resorption times and to produce no significant immunological or tissue reaction pB-oblems.
Detailed Description It is well known that the ligamentum nuchae is made up largely of elastin, with only.a relatively small amount of collagen. Indeed, more than 703k of the dry weight of this ligament is elastin. Because of the relatively high elastin content and relatively low collagen ~c-ontent, it is an ideal starting material to us.e in making an injectable composition according to the present invention.
To make a preferred inj.ectable composition according to the present invention, the ligamentum nuchae may be cleaned using a procedure similar to that taught in U.S.P. 5,028,695. Generally, it is first cleaned o: blood and adherent tissue. It is then chemically treated to remove the non-elastinous and non-collagenous components. The chemical treatment generally involves first treating the ligament with a strong alkali solution, then with an acid, and then with a neutralizing agent. The alkali sequence may ~P
rep.eat.ed several times if ~3esired. Chemical treatment is followed by mechanical working to separate the elastin fibers. The separated fib>ers are then WO 95/07095 ~ PCTIUS94/10223 suspended in a suitable biocompatible carrier, for example a mixture of water and glycerin.
Although the preferred starting material is the ligamentum nuchae, other ligaments and tendons may also r be used. For example, the peritoneum, omentum and other animal membranes, especially those which have significant amounts of elastin, could be used. Also, elastin and collagen from different sources could be mixed together to produce a mix having whatever proportions are deemed advantageous for a particular application. It is believed, however, that the composition should have a.minimum of perhaps as little as about 10% elastin (dry weight) and might have as much as 90% or perhaps even higher of elastin.
While, as noted above, it is believed preferable not to use any cross-linking agents, there may be applications where cross-linking can be tolerated or might even be desirable. In that event, the cross-linking agent should be one which forms strong stable bonds with the collagen so that the cross-linking agent does not reach out and so that the cross-linked collagen is non-cytotoxic and does not provoke an immune or cellular response. Such cross-linking agents might include hexamethylene diisocyanate, some polyepoxy compounds, for example, polyethylene glycol diglycidyl ether, and some water soluble carbodiimides, for example, 1-ethyl-3[3-dimethyl amino propyl]carbodiimide.HCl in the presence of N-hydroxysuccinimide.
Exampla A portion of bovine ligamentum nuchae weighing about 10 kg. was soaked overnight in about 40 1. of tap water at room temperature to remove adherent blood and other water soluble components. Soaking in water also assures a more or less natural degree of hydration SUBSTITUTE SHEET (RULE 26) 2 ~.'~ '~ ~ 4 WO 95/07095 , . PCT/US94/10223 which is believed to facilitate the subsequent chemical treatments.
After the initial soak, the ligament was washed twice for about 10 minutes each, again in tap water, before , being placed in 50 1. of 4g (w/w) solution of sodium hydroxide (NaOH) in tap water. It was permitted to remain in this strongly alkaline soak for 48 hrs. at room temperature.
The alkaline soak was followed by three 10 minute washes in 50 1. of tap water and was then subjected to a second alkaline soak, this one in a 2~ (w/w) solution of NaOH in tap water at room temperature for 72 hrs.
There then followed three more 10 minute washes in tap water to remove the solubilized components.
After the second alkaline soak and subsequent washes, the ligament was placed in a solution of hydrochloric acid (HC1) for about 4 hrs. The HC1 solution for this soak was prepared by mixing 4 1. of concentrated (37~) HC1 with 36 1. of tap water. The acid soaked ligament was then washed in tap water until the pH of the water was between about 2.5 and 3.
At that point, the ligament was placed in a sodium bicarbonate (NaHC03) soak to neutralize the remaining acid. The NaHC03 soak was prepared by adding 350 gm. of NaHC03 to 50 1. of tap water. The ligament was left in this neutralizing bath overnight and then it was again washed in tap water to remove the resulting salts.
Washing continued until mixing with a silver nitrate (AgN03) solution produced no precipitates.
A kolloid mill was then used to break up the natural collagen/elastin matrix and separate the elastin fibers. Acetone extractions were then used to remove SUBSTITUTE SHEET (RULE 26) the water and the fibers were then air dried in an oven at about 75° C.
s Finally, 150 gm. of the dried fibers were suspended in 2 1. of a water/glycerine mixture comprised of 1 1.
water and 1 1. glycerine. This suspension was then ready for use in accordance with the present invention.
It is believed that the collagen in the composition according to this present invention acts as a stimulant during the initial phase after injection. It tends to cause some mild tissue reaction and increased vascular activity. Of course, this leads to resorption, but in the process, fibroblasts, which appear to have an affinity for elastin, invade the injected composition and attach themselves to the elastin fibers. Hence, these fibroblasts lay down an organized matrix of new native connective tissue. Eventually, the injected collagen has been resorbed and all that remains is the injected elastin in a new native connective tissue structure.
It will readily become apparent to those skilled in this art that numerous modifications, alterations and changes can be made with respect to the specifics of the above description without departing from the inventive concept described herein. Accordingly, all such variants should be viewed as being within the scope of the invention as set forth in the claims below.
SUBSTITUTE SHEET (RULE 26)
INJECTABLE COMPOSITIONS FOR
SOFT TISSUR Arrr_~~p,TION
BACKGROUND OF THE INVENTION
Field of the Invention The present invention relates to injectable compositions having primary utility for soft tissue augmentation.
Related Background Over the years, many attempts have been made to develop injectable compositions for soft tissue augmentation, especially breast augmentation. Although in recent years the emphasis in breast augmentation has been on surgically implantable breast prostheses, injectable compositions offer the very important advantage of being able to avoid a surgical procedure.
Some of the early attempts to make injectable compositions for breast augmentation involved the use of silicone gel. However, silicone injected subcutaneously has a tendency to migrate into the surrounding tissue causing, among other problems, SUBSTITUTE SHEET (RULE 26) WO 95/07095 PCTlUS9.~/10223 granulomas. Accordingly, injectable liquid gels are no longer in use.
Subsequently, injectable collagen in suspension became the composition of choice. However, natural collagen , has a great tendency to be resorbed. Therefore, in order to have soft tissue augmentation that did not dissipate shortly after injection, it was found necessary to cross link the collagen with agents such as glutaraldehyde. Cross linking inhibits resorption.
However, recently the use of glutaraldehyde cross linked collagen has itself come under attack.
SUN~ARY OF THE INVENTION
The present invention addresses the problems encountered in the prior art by using injectable compositions containing non-cross linked collagen together with significant amounts of elastin. Elastin has a much lower tendency than collagen toward resorption. Moreover, it is believed that elastin attracts fibroblasts which in turn produce new native connective tissue. Thus, when a composition according to the present invention is injected subcutaneously into soft tissue, as the injected collagen is being resorbed, new native connective tissue is being generated, until a steady state situation has been achieved.
Another advantage of using elastin is that, in suspension, it has a lower viscosity and hence flows much more readily than collagen. This characteristic of elastin makes it easier to inject higher solids content compositions than is possible when using collagen alone.
As indicated above, one use for the compositions of the present invention is for breast augmentation. Another SUBSTITUTE SHEET (RULE 26) WO 95/07095 ; PCT/US94/10223 cosmetic application is as a dermal implant to remove wrinkles, primarily around the face and neck. In addition, there are medical applications as well. For a example, compositions of the present invention can be used in connection with overcoming urinary incontinence. In this latter application, a composition according to the present invention would be injected into the area of the urethral sphincter.
Other possible uses for the compositions of the present invention include load-bearing tissue augmentation, for example, under a corn, and general and specific contour improvements, for example, for nose contour corrections and to correct viral pock marks and acne scars. For load bearing tissue augmentation, the composition of the present invention would be injected between the load bearing tissue, for example the corn, and the load exerting medium, for example the bone. To alleviate skin contour defects, such as viral infection pock marks and acne scars, the composition of the present invention would be injected into the soft tissue beneath the imperfection. Similarly, to change the contour of a person's nose, the composition of the present invention would be injected into the soft tissue of the nose.
While collagen has been used previously for the above-described applications, it has generally been in the form of cross-linked collagen. Even with cross-linked collagen, however, the resorption time is often unacceptably short, especially after repeated injections. Indeed, injections of cross-linked collagen must frequently be repeated several times over a short time span before adequate augmentation can be achieved. In addition, glutaraldehyde cross-linked collagen tends to cause tissue reactions in some patients and, also, there is some concern about SUBSTITUTE SHEET (RULE 26) potential immunolcgical problems associated with the use of collagen that has been cross-linked with glutaraldehyde. Cross linking agents like glutaraldehyde are known to be toxic and there is S concern that repeated injections of glutaraldehyde-containing compositions may produce: progressively more severe immune reactions and increasingly rapid resorption. The compositions of tree present invention, on the other hand, are believed to have much longer resorption times and to produce no significant immunological or tissue reaction pB-oblems.
Detailed Description It is well known that the ligamentum nuchae is made up largely of elastin, with only.a relatively small amount of collagen. Indeed, more than 703k of the dry weight of this ligament is elastin. Because of the relatively high elastin content and relatively low collagen ~c-ontent, it is an ideal starting material to us.e in making an injectable composition according to the present invention.
To make a preferred inj.ectable composition according to the present invention, the ligamentum nuchae may be cleaned using a procedure similar to that taught in U.S.P. 5,028,695. Generally, it is first cleaned o: blood and adherent tissue. It is then chemically treated to remove the non-elastinous and non-collagenous components. The chemical treatment generally involves first treating the ligament with a strong alkali solution, then with an acid, and then with a neutralizing agent. The alkali sequence may ~P
rep.eat.ed several times if ~3esired. Chemical treatment is followed by mechanical working to separate the elastin fibers. The separated fib>ers are then WO 95/07095 ~ PCTIUS94/10223 suspended in a suitable biocompatible carrier, for example a mixture of water and glycerin.
Although the preferred starting material is the ligamentum nuchae, other ligaments and tendons may also r be used. For example, the peritoneum, omentum and other animal membranes, especially those which have significant amounts of elastin, could be used. Also, elastin and collagen from different sources could be mixed together to produce a mix having whatever proportions are deemed advantageous for a particular application. It is believed, however, that the composition should have a.minimum of perhaps as little as about 10% elastin (dry weight) and might have as much as 90% or perhaps even higher of elastin.
While, as noted above, it is believed preferable not to use any cross-linking agents, there may be applications where cross-linking can be tolerated or might even be desirable. In that event, the cross-linking agent should be one which forms strong stable bonds with the collagen so that the cross-linking agent does not reach out and so that the cross-linked collagen is non-cytotoxic and does not provoke an immune or cellular response. Such cross-linking agents might include hexamethylene diisocyanate, some polyepoxy compounds, for example, polyethylene glycol diglycidyl ether, and some water soluble carbodiimides, for example, 1-ethyl-3[3-dimethyl amino propyl]carbodiimide.HCl in the presence of N-hydroxysuccinimide.
Exampla A portion of bovine ligamentum nuchae weighing about 10 kg. was soaked overnight in about 40 1. of tap water at room temperature to remove adherent blood and other water soluble components. Soaking in water also assures a more or less natural degree of hydration SUBSTITUTE SHEET (RULE 26) 2 ~.'~ '~ ~ 4 WO 95/07095 , . PCT/US94/10223 which is believed to facilitate the subsequent chemical treatments.
After the initial soak, the ligament was washed twice for about 10 minutes each, again in tap water, before , being placed in 50 1. of 4g (w/w) solution of sodium hydroxide (NaOH) in tap water. It was permitted to remain in this strongly alkaline soak for 48 hrs. at room temperature.
The alkaline soak was followed by three 10 minute washes in 50 1. of tap water and was then subjected to a second alkaline soak, this one in a 2~ (w/w) solution of NaOH in tap water at room temperature for 72 hrs.
There then followed three more 10 minute washes in tap water to remove the solubilized components.
After the second alkaline soak and subsequent washes, the ligament was placed in a solution of hydrochloric acid (HC1) for about 4 hrs. The HC1 solution for this soak was prepared by mixing 4 1. of concentrated (37~) HC1 with 36 1. of tap water. The acid soaked ligament was then washed in tap water until the pH of the water was between about 2.5 and 3.
At that point, the ligament was placed in a sodium bicarbonate (NaHC03) soak to neutralize the remaining acid. The NaHC03 soak was prepared by adding 350 gm. of NaHC03 to 50 1. of tap water. The ligament was left in this neutralizing bath overnight and then it was again washed in tap water to remove the resulting salts.
Washing continued until mixing with a silver nitrate (AgN03) solution produced no precipitates.
A kolloid mill was then used to break up the natural collagen/elastin matrix and separate the elastin fibers. Acetone extractions were then used to remove SUBSTITUTE SHEET (RULE 26) the water and the fibers were then air dried in an oven at about 75° C.
s Finally, 150 gm. of the dried fibers were suspended in 2 1. of a water/glycerine mixture comprised of 1 1.
water and 1 1. glycerine. This suspension was then ready for use in accordance with the present invention.
It is believed that the collagen in the composition according to this present invention acts as a stimulant during the initial phase after injection. It tends to cause some mild tissue reaction and increased vascular activity. Of course, this leads to resorption, but in the process, fibroblasts, which appear to have an affinity for elastin, invade the injected composition and attach themselves to the elastin fibers. Hence, these fibroblasts lay down an organized matrix of new native connective tissue. Eventually, the injected collagen has been resorbed and all that remains is the injected elastin in a new native connective tissue structure.
It will readily become apparent to those skilled in this art that numerous modifications, alterations and changes can be made with respect to the specifics of the above description without departing from the inventive concept described herein. Accordingly, all such variants should be viewed as being within the scope of the invention as set forth in the claims below.
SUBSTITUTE SHEET (RULE 26)
Claims (17)
1. An injectable implant composition for soft tissue augmentation comprising elastin and collagen and a biocompatible carrier:
2. A composition according to claim 1 wherein said elastin is at least 10% by weight of the combined dry weight of elastin plus collagen.
3. A composition according to claim 1 wherein sand elastin content is at least 50% of said combined dry weight.
4. A composition according to claim 1 wherein said elastin content is at least 70% of said combined weight.
5. A composition according to claim 1 wherein same of said elastin is derived from a tissue source difference from the tissue source from which some of the collagen was derived.
6. A composition according to claim 3 wherein said collagen and elastin have been treated to remove non-ccllagenous and non-elastinous proteins.
7. A composition according to claim 1 wherein said collagen has not beer. cross-linked.
8. A composition according to claim 1 wherein said collagen has been cross-linked with a compound selected from the group consisting of hexamethylene diiosocyanate, a polyepoxy and a water soluble carbodiimide.
9. An injectable implant composition comprised of elastin and collagen for soft tissue augmentation derived from the ligamaentum nuchae which has been treated to remove non-collagenous and non-elastinous proteins.
10. Use for treating urinary incontinence of the composition in accordance with claim 1.
11. A method of breast augmentation comprising injecting the composition in accordance with claim 1 into the breast.
12. A method of cosmetic treatment of wrinkles comprising injecting the composition in accordance with claim 1 into the soft tissue in or around the face.
13. Use for load bearing tissue augmentation of the composition in accordance with claim 1.
14. A method of treating acne scars or viral pock marks comprising injecting the composition in accordance with claim 1 into the soft tissue underlying said scar or pock mask.
15. A method of changing the contours of a nose comprising injecting the composition in accordance with claim 1 into the soft tissue of the nose.
16. A method of making an injectable implant composition for soft tissue augmentation from the ligamentum nuchae comprising the steps of - washing the ligamentum nuchae in water, - treating the washed ligamentum nuchae with a strong alkali solution, - treating the ligamentum nuchae with an acid, treating the ligamentum nuchae with a base to neutralize the acid, mechanically working the ligamentum nuchae to separate the elastin fibers, - suspending some of the collagen and elastin fibers in a carrier.
17. A method of making an injectable implant composition for soft tissue augmentation comprising the steps of - selecting tissue starting material from the group consisting of animal ligaments, tendons and membranes, - washing said tissue in water, - treating the washed tissue with a strong alkali solution, treating the tissue with an and, - treating the tissue with a base to neutralize the acid, - mechanically working the tissue to separate the elastin fibers, - suspending some of the elastin fibers in a carrier.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/116,517 US5523291A (en) | 1993-09-07 | 1993-09-07 | Injectable compositions for soft tissue augmentation |
US08/116,517 | 1993-09-07 | ||
PCT/US1994/010223 WO1995007095A1 (en) | 1993-09-07 | 1994-09-07 | Injectable compositions for soft tissue augmentation |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2170754A1 CA2170754A1 (en) | 1995-03-16 |
CA2170754C true CA2170754C (en) | 2006-07-11 |
Family
ID=22367654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002170754A Expired - Fee Related CA2170754C (en) | 1993-09-07 | 1994-09-07 | Injectable compositions for soft tissue augmentation |
Country Status (13)
Country | Link |
---|---|
US (2) | US5523291A (en) |
EP (1) | EP0717634B1 (en) |
KR (1) | KR100333088B1 (en) |
CN (1) | CN1142789C (en) |
AT (1) | ATE210992T1 (en) |
AU (1) | AU675879B2 (en) |
BR (1) | BR9407420A (en) |
CA (1) | CA2170754C (en) |
DE (1) | DE69429522T2 (en) |
DK (1) | DK0717634T3 (en) |
ES (1) | ES2169085T3 (en) |
PT (1) | PT717634E (en) |
WO (1) | WO1995007095A1 (en) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5606019A (en) * | 1987-10-29 | 1997-02-25 | Protien Polymer Technologies, Inc. | Synthetic protein as implantables |
US7060287B1 (en) * | 1992-02-11 | 2006-06-13 | Bioform Inc. | Tissue augmentation material and method |
US6537574B1 (en) | 1992-02-11 | 2003-03-25 | Bioform, Inc. | Soft tissue augmentation material |
US7968110B2 (en) * | 1992-02-11 | 2011-06-28 | Merz Aesthetics, Inc. | Tissue augmentation material and method |
US5676698A (en) * | 1993-09-07 | 1997-10-14 | Datascope Investment Corp. | Soft tissue implant |
US5523291A (en) * | 1993-09-07 | 1996-06-04 | Datascope Investment Corp. | Injectable compositions for soft tissue augmentation |
US6334872B1 (en) * | 1994-02-18 | 2002-01-01 | Organogenesis Inc. | Method for treating diseased or damaged organs |
US20020095218A1 (en) | 1996-03-12 | 2002-07-18 | Carr Robert M. | Tissue repair fabric |
US5993844A (en) * | 1997-05-08 | 1999-11-30 | Organogenesis, Inc. | Chemical treatment, without detergents or enzymes, of tissue to form an acellular, collagenous matrix |
US6371992B1 (en) * | 1997-12-19 | 2002-04-16 | The Regents Of The University Of California | Acellular matrix grafts: preparation and use |
US6809075B1 (en) | 2000-05-30 | 2004-10-26 | Connective Tissue Imagineering Llc | Elastin peptide analogs and uses of same incombination with skin enhancing agents |
US6962904B1 (en) * | 1998-03-13 | 2005-11-08 | Connective Tissue Imagineering | Elastin peptide analogs and uses thereof |
US6069129A (en) * | 1998-03-13 | 2000-05-30 | Mrs, Llc | Elastin derived composition and method of using same |
JP4341049B2 (en) * | 1998-06-05 | 2009-10-07 | オルガノジェネシス インク. | Tubular graft prosthesis made by biotechnology |
JP4606583B2 (en) * | 1998-06-05 | 2011-01-05 | オルガノジェネシス インク. | Planar sheet transplant prosthesis using biotechnological techniques |
CA2334228C (en) * | 1998-06-05 | 2010-09-28 | Organogenesis Inc. | Bioengineered vascular graft support prostheses |
JP4341050B2 (en) * | 1998-06-05 | 2009-10-07 | オルガノジェネシス インク. | Vascular graft prosthesis made by bioengineering |
GB2345638A (en) * | 1998-09-11 | 2000-07-19 | Tissue Science Lab Limited | Injectable collagen compositions |
US6777389B1 (en) | 1998-11-19 | 2004-08-17 | Connective Tissue Imagineering Llc | Cosmetic or dermatological use of 7-hydroxylated steroids in combination with elastin derived peptides |
JP2002537910A (en) * | 1999-03-01 | 2002-11-12 | アドバンスト バイオメディカル デバイシィズ インコーポレイテッド | Implant positioning system and method |
US6866686B2 (en) * | 2000-01-28 | 2005-03-15 | Cryolife, Inc. | Tissue graft |
US6794362B1 (en) | 2000-05-30 | 2004-09-21 | Connective Tissue Imagineering Llc | Asparagine containing elastin peptide analogs |
EP1320390A2 (en) * | 2000-09-18 | 2003-06-25 | Organogenesis Inc. | Bioengineered flat sheet graft prosthesis and its use |
CN1227040C (en) * | 2001-09-05 | 2005-11-16 | 韩士生科有限公司 | Production of biomaterial for tissue restoration |
US20030181371A1 (en) * | 2001-12-28 | 2003-09-25 | Angiotech Pharmaceuticals, Inc. | Compositions and methods of using collajolie |
US7064187B2 (en) | 2002-11-26 | 2006-06-20 | Crosscart, Inc. | Substantially non-immunogenic injectable collagen |
KR20050086949A (en) * | 2002-12-27 | 2005-08-30 | 안지오테크 인터내셔날 아게 | Compositions and methods of using collajolie |
US8138265B2 (en) * | 2003-01-10 | 2012-03-20 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
US7465766B2 (en) * | 2004-01-08 | 2008-12-16 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
US8137688B2 (en) * | 2003-01-10 | 2012-03-20 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
FR2850282B1 (en) * | 2003-01-27 | 2007-04-06 | Jerome Asius | INJECTABLE IMPLANT BASED ON CERAMIC FOR THE FILLING OF WRINKLES, CUTANEOUS DEPRESSIONS AND SCARS, AND ITS PREPARATION |
US7597660B2 (en) * | 2003-09-19 | 2009-10-06 | Broockeville Corporation B.V. | Incontinence therapy |
EP1516636A3 (en) * | 2003-09-19 | 2005-08-03 | Broockeville Corporation N.V. | Use of a curable elastomer-precursor for a medical treatment |
EP1691852A2 (en) * | 2003-11-10 | 2006-08-23 | Angiotech International AG | Medical implants and fibrosis-inducing agents |
US8124120B2 (en) * | 2003-12-22 | 2012-02-28 | Anika Therapeutics, Inc. | Crosslinked hyaluronic acid compositions for tissue augmentation |
US20050209695A1 (en) * | 2004-03-15 | 2005-09-22 | De Vries Jan A | Vertebroplasty method |
US20050228216A1 (en) * | 2004-04-08 | 2005-10-13 | Vries Jan A D | Method for treating gastroesophageal reflux disease |
CN1294994C (en) * | 2004-07-05 | 2007-01-17 | 暨南大学 | Injectable type collagen-based soft tissue filling material and preparation method thereof |
US9788821B2 (en) * | 2005-04-29 | 2017-10-17 | Cook Biotech Incorporated | Physically modified extracellular matrix materials and uses thereof |
KR20080026198A (en) * | 2005-06-30 | 2008-03-24 | 안트로제네시스 코포레이션 | Repair of tympanic membrane using placenta derived collagen biofabric |
US20070184087A1 (en) | 2006-02-06 | 2007-08-09 | Bioform Medical, Inc. | Polysaccharide compositions for use in tissue augmentation |
WO2008021391A1 (en) * | 2006-08-15 | 2008-02-21 | Anthrogenesis Corporation | Umbilical cord biomaterial for medical use |
GB0618215D0 (en) * | 2006-09-15 | 2006-10-25 | Novathera Ltd | Composite material |
WO2008042441A1 (en) * | 2006-10-03 | 2008-04-10 | Anthrogenesis Corporation | Use of umbilical cord biomaterial for ocular surgery |
WO2008060377A2 (en) | 2006-10-04 | 2008-05-22 | Anthrogenesis Corporation | Placental or umbilical cord tissue compositions |
CA3178363A1 (en) | 2006-10-06 | 2008-05-15 | Celularity Inc. | Human placental collagen compositions, and methods of making and using the same |
CN103861148A (en) | 2006-11-13 | 2014-06-18 | 悉尼大学 | Use of tropoelastin for repair or restoration of tissue |
US9056151B2 (en) * | 2007-02-12 | 2015-06-16 | Warsaw Orthopedic, Inc. | Methods for collagen processing and products using processed collagen |
US20080260794A1 (en) * | 2007-02-12 | 2008-10-23 | Lauritzen Nels J | Collagen products and methods for producing collagen products |
EP2178576A2 (en) * | 2007-04-16 | 2010-04-28 | Tissue Science Laboratories PLC | Bone implant |
US20100179639A1 (en) * | 2007-04-16 | 2010-07-15 | Stephen Bloor | Vascular implant |
EP2520309A1 (en) * | 2007-07-27 | 2012-11-07 | Humacyte, Inc. | Compositions and methods for soft tissue augmentation |
ES2585483T3 (en) * | 2008-02-13 | 2016-10-06 | The Cleveland Clinic Foundation | Molecular improvement of the extracellular matrix and methods of use |
KR100947553B1 (en) * | 2008-02-14 | 2010-03-12 | 주식회사 바이오랜드 | Biological implantation material and method for preparing same |
US8410180B2 (en) * | 2008-04-30 | 2013-04-02 | The Cleveland Clinic Foundation | Methods to treat urinary incontinence |
EP2358409B1 (en) * | 2008-06-20 | 2017-01-18 | Cook Biotech Incorporated | Compressible/expandable medical graft products, and methods for applying hemostasis |
US9248165B2 (en) | 2008-11-05 | 2016-02-02 | Hancock-Jaffe Laboratories, Inc. | Composite containing collagen and elastin as a dermal expander and tissue filler |
US20110020271A1 (en) * | 2009-05-20 | 2011-01-27 | Humacyte, Inc. | Elastin for soft tissue augmentation |
US8192456B2 (en) * | 2009-07-13 | 2012-06-05 | Vascular Solutions, Inc. | Metal vascular aperture closure device |
US8460691B2 (en) | 2010-04-23 | 2013-06-11 | Warsaw Orthopedic, Inc. | Fenestrated wound repair scaffold |
US8790699B2 (en) | 2010-04-23 | 2014-07-29 | Warsaw Orthpedic, Inc. | Foam-formed collagen strand |
US20130011451A1 (en) | 2011-07-06 | 2013-01-10 | Diversified Glogal Technologies, Llc | Footbed with non-denatured collagen |
AU2015217406A1 (en) * | 2014-02-11 | 2016-08-25 | Celularity Inc. | Micro-organoids, and methods of making and using the same |
US9993578B1 (en) * | 2017-01-12 | 2018-06-12 | Lorstan Pharmaceutical, LLC | Silicone oil-in-water composition useful as an injectable filler and as a scaffold for collagen growth |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4488911A (en) * | 1975-10-22 | 1984-12-18 | Luck Edward E | Non-antigenic collagen and articles of manufacture |
US4233360A (en) * | 1975-10-22 | 1980-11-11 | Collagen Corporation | Non-antigenic collagen and articles of manufacture |
CA1073360A (en) * | 1975-10-22 | 1980-03-11 | John R. Daniels | Non-antigenic collagen and articles of manufacture |
DE2705670C3 (en) * | 1977-02-11 | 1983-11-17 | Fa. Carl Freudenberg, 6940 Weinheim | Process for the production of water-soluble elastin hydrolysates |
CA1190855A (en) * | 1980-09-03 | 1985-07-23 | Rolf W. Pfirrmann | Treatment of osteitis |
US4378224A (en) * | 1980-09-19 | 1983-03-29 | Nimni Marcel E | Coating for bioprosthetic device and method of making same |
US4424208A (en) * | 1982-01-11 | 1984-01-03 | Collagen Corporation | Collagen implant material and method for augmenting soft tissue |
US4960423A (en) * | 1982-11-17 | 1990-10-02 | Smith Donald W | Method of enhancing the attachment of endothelial cells on a matrix and vascular prosthesis with enhanced anti-thrombogenic characteristics |
US4692552A (en) * | 1983-05-09 | 1987-09-08 | G. D. Searle & Co. | Protease inhibitors |
US4801299A (en) * | 1983-06-10 | 1989-01-31 | University Patents, Inc. | Body implants of extracellular matrix and means and methods of making and using such implants |
US4601896A (en) * | 1984-03-21 | 1986-07-22 | Mark Nugent | Pharmaceutical capsule compositions and structures for gastric sensitive materials |
US4837285A (en) * | 1984-03-27 | 1989-06-06 | Medimatrix | Collagen matrix beads for soft tissue repair |
US4642117A (en) * | 1985-03-22 | 1987-02-10 | Collagen Corporation | Mechanically sheared collagen implant material and method |
US4649147A (en) * | 1985-07-08 | 1987-03-10 | G. D. Searle & Co. | Treating elastin degradation with 1-(alkenoyl)azacycloalkyl carboxylic acids and derivatives |
US4803075A (en) * | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
GB8618374D0 (en) * | 1986-07-28 | 1986-09-03 | Hsc Res Dev Corp | Biological vascular prostheses |
GB8708009D0 (en) * | 1987-04-03 | 1987-05-07 | Clayton Found Res | Injectable soft tissue augmentation materials |
ES2060614T3 (en) * | 1988-03-11 | 1994-12-01 | Chemokol G B R Ing Buro Fur Ko | PROCEDURE FOR THE MANUFACTURE OF COLLAGEN MEMBRANES FOR HEMOSTASIS, WOUND TREATMENT AND IMPLANTS. |
US5024841A (en) * | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
US4950483A (en) * | 1988-06-30 | 1990-08-21 | Collagen Corporation | Collagen wound healing matrices and process for their production |
US5110604A (en) * | 1988-06-30 | 1992-05-05 | Collagen Corporation | Processes for producing collagen matrixes and methods of using same |
US5138030A (en) * | 1989-10-10 | 1992-08-11 | Pachence James M | Process for extracting type I collagen form an avian source, and applications therefor |
US5206028A (en) * | 1991-02-11 | 1993-04-27 | Li Shu Tung | Dense collagen membrane matrices for medical uses |
US5204382A (en) * | 1992-02-28 | 1993-04-20 | Collagen Corporation | Injectable ceramic compositions and methods for their preparation and use |
US5523291A (en) * | 1993-09-07 | 1996-06-04 | Datascope Investment Corp. | Injectable compositions for soft tissue augmentation |
-
1993
- 1993-09-07 US US08/116,517 patent/US5523291A/en not_active Expired - Fee Related
-
1994
- 1994-09-07 PT PT94927397T patent/PT717634E/en unknown
- 1994-09-07 ES ES94927397T patent/ES2169085T3/en not_active Expired - Lifetime
- 1994-09-07 DE DE69429522T patent/DE69429522T2/en not_active Expired - Lifetime
- 1994-09-07 AT AT94927397T patent/ATE210992T1/en not_active IP Right Cessation
- 1994-09-07 CN CNB941938328A patent/CN1142789C/en not_active Expired - Fee Related
- 1994-09-07 EP EP94927397A patent/EP0717634B1/en not_active Expired - Lifetime
- 1994-09-07 AU AU76857/94A patent/AU675879B2/en not_active Ceased
- 1994-09-07 DK DK94927397T patent/DK0717634T3/en active
- 1994-09-07 KR KR1019960701112A patent/KR100333088B1/en not_active IP Right Cessation
- 1994-09-07 WO PCT/US1994/010223 patent/WO1995007095A1/en active IP Right Grant
- 1994-09-07 CA CA002170754A patent/CA2170754C/en not_active Expired - Fee Related
- 1994-09-07 BR BR9407420A patent/BR9407420A/en not_active Application Discontinuation
-
1996
- 1996-01-22 US US08/589,455 patent/US5705488A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US5705488A (en) | 1998-01-06 |
ATE210992T1 (en) | 2002-01-15 |
EP0717634A4 (en) | 1999-03-17 |
EP0717634A1 (en) | 1996-06-26 |
ES2169085T3 (en) | 2002-07-01 |
PT717634E (en) | 2002-06-28 |
KR100333088B1 (en) | 2002-09-12 |
US5523291A (en) | 1996-06-04 |
CN1133562A (en) | 1996-10-16 |
EP0717634B1 (en) | 2001-12-19 |
CN1142789C (en) | 2004-03-24 |
JP3596892B2 (en) | 2004-12-02 |
BR9407420A (en) | 1996-11-12 |
DE69429522T2 (en) | 2002-08-01 |
WO1995007095A1 (en) | 1995-03-16 |
AU675879B2 (en) | 1997-02-20 |
DE69429522D1 (en) | 2002-01-31 |
CA2170754A1 (en) | 1995-03-16 |
KR960704562A (en) | 1996-10-09 |
AU7685794A (en) | 1995-03-27 |
JPH09502372A (en) | 1997-03-11 |
DK0717634T3 (en) | 2002-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2170754C (en) | Injectable compositions for soft tissue augmentation | |
EP0717607B1 (en) | Improved soft tissue implant | |
US4515637A (en) | Collagen-thrombin compositions | |
US5081106A (en) | Wound dressing protocol utilizing collagen gelatin formed with iodine | |
US5128136A (en) | Wound healing kit comprised of gelable collagen | |
US4399123A (en) | Fibrous tissue dressing or implant | |
DE69925632T2 (en) | METHOD FOR TISSUE FIXING BY MEANS OF EPOXIDES | |
EP0509833A1 (en) | An intracorporeally injectable composition for implanting highly concentrated cross-linked atelocollagen | |
JPH01265970A (en) | Collagen water solution or water dispersion solution including hyaluronic acid | |
WO2008072839A1 (en) | Dermal filler composition | |
JPH0552751B2 (en) | ||
EP0089145B1 (en) | Injectable cross-linked collagen implant material | |
JP2873082B2 (en) | Grafts for use in bone surgery | |
Arem | Collagen modifications | |
JP3596892B6 (en) | Injectable composition for soft tissue augmentation | |
JPS58170796A (en) | Injectable bridged collagen, preparation and transplantation substance of collagen | |
Elson | Update on soft tissue augmentation | |
CN112022735A (en) | Novel collagen mask and preparation method thereof | |
Kim et al. | TISSUE CHANGE AFTER EMBEDDING GELATIN MATRIX IMPLANT (FFIBREL®) IN SUBCUTANEOUS TISSUE OF RATS; HISTOLOGIC, IMMUNOHISTOCHEMICAL AND SCANNING ELECTRON MICROSCOPIC STUDY | |
CS269196B1 (en) | Biocompatible collagenous material and method of its preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |